Skip to main content
Erschienen in: Medical Oncology 4/2012

01.12.2012 | Original Paper

Expression and clinical significance of NEDD9 in lung tissues

verfasst von: Jing-Xia Chang, Feng Gao, Guo-Qiang Zhao, Guo-Jun Zhang

Erschienen in: Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Neural precursor cell expressed, developmentally downregulated 9 (NEDD9) acts as a scaffold protein and belongs to a family of CAS (Crk-associated substrate) that regulates protein complexes controlling invasion and differentiation. Preclinical research for this gene was predominantly reported in melanomas, glioblastoma, and lymphoma. So we investigated the expression and significance of NEDD9 mRNA and protein in lung tissues. Specifically, we immunohistochemically compared NEDD9 expression and localization in 24 formalin-fixed and paraffin-embedded lung adenocarcinoma tissues with that of surrounding nonneoplastic tissue and five microscopically normal lungs. NEDD9 mRNA levels were quantitatively analyzed by fluorescent quantitative reverse transcription–polymerase chain reaction (FQ-PCR) in frozen tissue specimens of all tumors and 24 matched nonneoplastic lung parenchymas, and protein expression in 16 homogenates of matched neoplastic/nonneoplastic specimens was evaluated by Western blotting. The three techniques showed that NEDD9 is weakly expressed in nonneoplastic lung parenchyma and upregulated in lung adenocarcinoma. Moreover, FQ-PCR indicated a statistically significant correlation between NEDD9 upregulation and higher disease stages (I + II versus III + IV, p = 0.001; high and middle versus low differentiation, p < 0.001). Our results provide evidence that NEDD9 is upregulated in lung adenocarcinoma, and overexpression of NEDD9 protein has been strongly correlated with staging and differentiation grade and tumor size in lung adenocarcinoma, which demonstrated a poor prognosis.
Literatur
1.
Zurück zum Zitat Law SF, Estojak J, Wang B, et al. Human enhancer of filamentation 1 (HEF1/NEDD9/CAS-L), a novel p130Cas-Like docking protein, associates with FAK, and induces pseudohyphal growth in yeast. Mol Cell Biol. 1996;16:3327–37.PubMed Law SF, Estojak J, Wang B, et al. Human enhancer of filamentation 1 (HEF1/NEDD9/CAS-L), a novel p130Cas-Like docking protein, associates with FAK, and induces pseudohyphal growth in yeast. Mol Cell Biol. 1996;16:3327–37.PubMed
2.
Zurück zum Zitat Minegishi M, Tachibana K, Sato T, et al. Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta-1 integrin-mediated signaling in lymphocytes. J Exp Med. 1996;184:1365–75.PubMedCrossRef Minegishi M, Tachibana K, Sato T, et al. Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta-1 integrin-mediated signaling in lymphocytes. J Exp Med. 1996;184:1365–75.PubMedCrossRef
3.
Zurück zum Zitat Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun. 1992;185:1155–61.PubMedCrossRef Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun. 1992;185:1155–61.PubMedCrossRef
4.
Zurück zum Zitat Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cellular Mol Life Sci. 2010;67(7):1025–48.CrossRef Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cellular Mol Life Sci. 2010;67(7):1025–48.CrossRef
5.
Zurück zum Zitat Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–24.PubMedCrossRef Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–24.PubMedCrossRef
6.
Zurück zum Zitat Natarajan M, Stewart JE, Golemis EA, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene. 2006;25:1721–32.PubMedCrossRef Natarajan M, Stewart JE, Golemis EA, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene. 2006;25:1721–32.PubMedCrossRef
7.
Zurück zum Zitat Kim M, Gans JD, Nogueira C, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006;125:1269–81.PubMedCrossRef Kim M, Gans JD, Nogueira C, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006;125:1269–81.PubMedCrossRef
8.
Zurück zum Zitat Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
9.
Zurück zum Zitat Tuveson DA, Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene. 1999;18:5318–24.PubMedCrossRef Tuveson DA, Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene. 1999;18:5318–24.PubMedCrossRef
10.
Zurück zum Zitat Carelli S, Zadra G, Vaira V, et al. Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2006;53:263–71.CrossRef Carelli S, Zadra G, Vaira V, et al. Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2006;53:263–71.CrossRef
11.
Zurück zum Zitat Liu N, Bi F, Pan Y, et al. Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res. 2004;10(18 Pt 1):6239–47.PubMedCrossRef Liu N, Bi F, Pan Y, et al. Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res. 2004;10(18 Pt 1):6239–47.PubMedCrossRef
12.
Zurück zum Zitat Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early-stage nonsmall cell lung cancer. J Pathol. 2003;200:620–6.PubMedCrossRef Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early-stage nonsmall cell lung cancer. J Pathol. 2003;200:620–6.PubMedCrossRef
13.
Zurück zum Zitat Astier A, Manie SN, Law SF, et al. Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma. 1997;28:65–72.PubMed Astier A, Manie SN, Law SF, et al. Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma. 1997;28:65–72.PubMed
14.
Zurück zum Zitat le Thao B, Vu HA, Yasuda K, et al. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. Cancer Biol Ther. 2009;8:683–8.CrossRef le Thao B, Vu HA, Yasuda K, et al. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. Cancer Biol Ther. 2009;8:683–8.CrossRef
15.
Zurück zum Zitat Iwata S, Souta-Kuribara A, Yamakawa A, et al. HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L). Oncogene. 2005;24:1262–71.PubMedCrossRef Iwata S, Souta-Kuribara A, Yamakawa A, et al. HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L). Oncogene. 2005;24:1262–71.PubMedCrossRef
16.
Zurück zum Zitat Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007;448:807–10.PubMedCrossRef Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007;448:807–10.PubMedCrossRef
17.
Zurück zum Zitat Fashena SJ, Einarson MB, O’Neill GM, et al. Dissection of HEF1-dependent functions in motility and transcriptional regulation. J Cell Sci. 2002;115:99–111.PubMed Fashena SJ, Einarson MB, O’Neill GM, et al. Dissection of HEF1-dependent functions in motility and transcriptional regulation. J Cell Sci. 2002;115:99–111.PubMed
18.
Zurück zum Zitat Law SF, O’Neill GM, Fashena SJ, et al. The docking protein HEF1/NEDD9/CAS-L is an apoptotic mediator at focal adhesion sites. Mol Cell Biol. 2000;20:5184–95.PubMedCrossRef Law SF, O’Neill GM, Fashena SJ, et al. The docking protein HEF1/NEDD9/CAS-L is an apoptotic mediator at focal adhesion sites. Mol Cell Biol. 2000;20:5184–95.PubMedCrossRef
19.
Zurück zum Zitat Pugacheva EN, Golemis EA. The focal adhesion scaffolding protein HEF1/NEDD9/CAS-L regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol. 2005;7:937–46.PubMedCrossRef Pugacheva EN, Golemis EA. The focal adhesion scaffolding protein HEF1/NEDD9/CAS-L regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol. 2005;7:937–46.PubMedCrossRef
20.
Zurück zum Zitat Nakamoto T, Sakai R, Honda H, et al. Requirements for localization of p130cas to focal adhesions. Mol Cell Biol. 1997;17:3884–97.PubMed Nakamoto T, Sakai R, Honda H, et al. Requirements for localization of p130cas to focal adhesions. Mol Cell Biol. 1997;17:3884–97.PubMed
21.
Zurück zum Zitat van Seventer GA, Salmen HJ, Law SF, et al. Focal adhesion kinase regulates beta1 integrin-dependent T cell migration through an HEF1 effector pathway. Eur J Immunol. 2001;31:1417–27.PubMedCrossRef van Seventer GA, Salmen HJ, Law SF, et al. Focal adhesion kinase regulates beta1 integrin-dependent T cell migration through an HEF1 effector pathway. Eur J Immunol. 2001;31:1417–27.PubMedCrossRef
Metadaten
Titel
Expression and clinical significance of NEDD9 in lung tissues
verfasst von
Jing-Xia Chang
Feng Gao
Guo-Qiang Zhao
Guo-Jun Zhang
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0213-0

Weitere Artikel der Ausgabe 4/2012

Medical Oncology 4/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.